Approval of New Class 1 Drug ADC by Lepu Biopharma for Clinical Trials
Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Lepu Biopharma’s Class 1 new drug MRG007 has been approved for clinical trials,aiming to develop treatments for locally advanced or metastatic solid tumors. Public information indicates that this is aCDH17-targeted antibody-drug conjugate (ADC),formed by conjugating a novel humanized … Read more